P265. Is standalone ALIF a safe and effective treatment for low grade Isthmic spondylolisthesis?

Greg M. Malham
DOI: https://doi.org/10.1016/j.spinee.2024.06.388
IF: 4.297
2024-08-20
The Spine Journal
Abstract:BACKGROUND CONTEXT There is a paucity of data examining anterior lumbar interbody fusion (ALIF) with (ALIF-PLF) or without (standalone, sa-ALIF) posterior fixation for treatment for low-grade (grade I or II) isthmic spondylolisthesis (IS); hence, it remains a topical debate amongst spine surgeons. Correcting pathology with sa-ALIF reduces costs, operative times, and posterior access complications. PURPOSE This study assesses sa-ALIF outcomes for low-grade IS and evaluates the need for posterior fixation based on comparison to an ALIF-PLF cohort. STUDY DESIGN/SETTING Comparative prospective analysis of cohort data. PATIENT SAMPLE Consecutive patients from 1 senior spine surgeon performing sa-ALIF or ALIF-PLF for management of low-grade IS between December 2013-2022. All patients had a normal sacral slope (<40 o ) and bone density on DEXA assessed radiographically preoperatively. Patients with a BMI >35 kg/m 2 were excluded. OUTCOME MEASURES Patient-reported outcome measures (PROMs) were collected at 6-week, 6-month, 12-month, and final follow-up time points. Computed tomography (CT) imaging conducted at either 6-, 12- or 24-months for interbody fusion status. METHODS Patient demographics recorded at baseline. Patient-reported outcome measures (PROMs) were collected at 6-week, 6-month, 12-month, and final follow-up time points. The timepoint of greatest clinical interest was 12-months. Computed tomography (CT) imaging conducted at either 6-, 12- or 24-months for interbody fusion status. RESULTS The cohort consisted of 32 patients (sa-ALIF 13, ALIF-PLF 19) with similar demographics. Mean age and BMI (sex) of sa-ALIF vs ALIF-PLF cohort was 44.1±12.1 years and 24.0±3.6 kg/m 2 (61.5% male) vs 49.6±11.9 years and 26.0±2.8 kg/m 2 (63.2% male). Only 3 participants were current smokers (sa-ALIF n=1). There were 2 double level procedures at L4/5 and L5/S1 with the remaining operated at L5/S1. There was 26 grade I IS (sa-ALIF 12, ALIF-PLF 14) and grade II IS (sa-ALIF 1, ALIF-PLF 5) participants. Between groups, there were no significant differences (p=0.05) in mean baseline PROMs, fusion time, estimated blood loss, and PROMs at all follow-up time points except for 6-weeks. Fusion was achieved at 6-months in 40.6% (sa-ALIF 53.8%, ALIF-PLF 31.6%), 12-/24-months in 93.8% (sa-ALIF 92.3%, ALIF-PLF 94.7%) of patients. Only 2 patients (1 in each group) with grade I IS remained unfused over the follow-up period. Both groups' PROMs significantly decreased to 12-months postoperatively. Six-week mean postoperative PROMs in sa-ALIF and ALIF-PLF groups respectively were; VAS leg (2.5±2.3 vs 4.9±1.7, p=0.002), VAS back (3.5±1.4 vs 3.4±1.9, p=0.9), ODI (16.3±7.5 vs 21.2±5.4, p=0.05), SF-12 physical (43.1±6.5 vs 36.0±4.6, p=0.0014), and SF-12 mental (56.5±7.5 vs 54.0±4.5, p=0.3). A total of 15.4% vs 21.1% of patients suffered complications in the sa-ALIF and ALIF-PLF groups. The ALIF-PLF cohort had one posterior fixation revision. CONCLUSIONS In selected patients with normal bone density and sacral slope with a BMI <35kg/m 2 , sa-ALIF is a safe (less complications) and effective (faster fusion rates, recovery of PROMs) treatment option for low grade IS without the need for supplementary posterior fixation. FDA Device/Drug Status This abstract does not discuss or include any applicable devices or drugs.
clinical neurology,orthopedics
What problem does this paper attempt to address?